Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1069 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2024-01-05 (tpr.org)
Primate facility proposal rankles Brazoria County residents
Potential neighbors are concerned about property values, disease.
Read more
2022-07-18 (fitchratings.com)
Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.’s (CRL) ‘BBB–’ Issuer Default Rating reflects its strong position as a leading drug discovery, nonclinical devel
Read more
2022-06-22 (digitaljournal.com)
Bioburden Testing Market Qualitative Insights on Application & Outlook by Share, Future Growth
Bioburden testing is a process of measuring viable microorganisms on medical devices, raw material, or package. The process helps in determining parameters for its sterilization process to ensure safety and effectiveness of medical devices.
Read more
2022-04-01 (bdtonline.com)
The Worldwide Clinical Trials Industry is Expected to Reach $49+ Billion by 2026 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Apr 1, 2022--
Read more
2022-02-03 (valdostadailytimes.com)
Charles River Laboratories Announces Wind Contract with Repsol for European Operations
WILMINGTON, Mass.--(BUSINESS WIRE)--Feb 3, 2022--
Read more
2022-01-28 (marketwatch.com)
Life Science Tools and Reagents Market 2022 Size, share, Growth, Analysis and Demand with Forecast Overview and Scope to 2027
Life Science Tools and Reagents Market study provides detailed information on market upcoming trends, new business development, drivers, capacities, and technologies. It covers changing dynamics of global Life Science Tools and Reagents market and
Read more
2019-12-19 (biopharmadive.com)
Charles River Labs to buy HemaCare for $380M, expanding in cell therapy
The contract researcher expects HemaCare will boost a cell therapy business that earns it about $100 million in annual revenue.
Read more
2019-02-14 (biopharmadive.com)
Charles River Labs snaps up early-stage CRO for $510M
Acquiring Citoxlab will build out the contract research organization's footprint into Eastern Europe.
Read more